ADBIOTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,620 KRW | -0.38% |
|
-0.19% | -20.00% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 10.63B 7.87M | Sales 2023 | 10.47B 7.75M | Capitalization | 29.93B 22.15M |
|---|---|---|---|---|---|
| Net income 2022 | 2.7B 2M | Net income 2023 | -2.86B -2.12M | EV / Sales 2022 | 3.28 x |
| Net Debt 2022 | 4.14B 3.07M | Net Debt 2023 | 4.2B 3.11M | EV / Sales 2023 | 3.26 x |
| P/E ratio 2022 |
28.3
x | P/E ratio 2023 |
-10.5
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.48% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.38% | ||
| 1 week | -0.19% | ||
| Current month | +5.22% | ||
| 1 month | +9.17% | ||
| 3 months | -17.48% | ||
| 6 months | -24.71% | ||
| Current year | -20.00% |
1 week
2 565.00
2 680.00
1 month
2 405.002 685.00
Current year
2 390.004 850.00
1 year
2 390.005 680.00
3 years
2 390.0013 500.00
5 years
2 390.0013 500.00
10 years
2 390.0013 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hong-Geol Jeong
CEO | Chief Executive Officer | 62 | - |
Nam-Hyeong Lee
CTO | Chief Tech/Sci/R&D Officer | 78 | - |
Woo-Bok Kim
AUD | Comptroller/Controller/Auditor | 42 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yang-Woo Jeon
BRD | Director/Board Member | 64 | - |
Hong-Geol Jeong
CEO | Chief Executive Officer | 62 | - |
Nam-Hyeong Lee
CTO | Chief Tech/Sci/R&D Officer | 78 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 2,620 | -0.38% | 12,237 |
| 24-05-16 | 2,630 | +0.57% | 15,275 |
| 24-05-14 | 2,615 | 0.00% | 9,710 |
| 24-05-13 | 2,615 | -0.38% | 6,115 |
| 24-05-10 | 2,625 | -0.57% | 4,857 |
End-of-day quote Korea S.E., May 16, 2024
More quotes
ADBiotech Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of veterinary drugs. The Company operates its business through two segments. Veterinary Medicine segment is engaged in the manufacture and sale of antibiotics, anticoccidial agents, antimicrobial agents, nervous system agents, synthetic antibacterial agents and others. The Supplementary Feed segment is engaged in the manufacture and sale of functional supplementary feeds and other products.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.00% | 17.7M | |
| -11.83% | 79.42B | |
| +28.00% | 3.8B | |
| -1.39% | 3.23B | |
| +21.28% | 1.75B | |
| -3.25% | 1.61B | |
| -18.63% | 1.36B | |
| -1.17% | 1.3B | |
| -6.77% | 1.22B | |
| +2.34% | 1.11B |
- Stock Market
- Equities
- A179530 Stock
